| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRSN | Common Stock | Purchase | $265K | +80.8K | +0.94% | $3.28 | 8.65M | May 31, 2022 | See footnotes | F1, F2, F3 |
| transaction | MRSN | Common Stock | Purchase | $47.2K | +14.8K | +0.17% | $3.20 | 8.66M | Jun 2, 2022 | See footnotes | F1, F2, F4 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS II and BCIPLS, the "Bain Capital Life Sciences Entities"). |
| F2 | Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.215 to $3.300, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.175 to $3.200, inclusive. |